Summary of retrospective studies describing combining JAK inhibitors in HCT protocols
| Reference . | # Patients . | Study Design . | Results . | Conclusions . |
|---|---|---|---|---|
| 38 | 100 | Retrospective | No adverse impact on early outcomes of HCT | Continuing JAK inhibitor therapy near to start of conditioning therapy is associated with very low risk of withdrawal symptoms |
| HCT was delayed in 2 patients due to significant clinical events following JAK 1/2 inhibitor discontinuation: 1 patient developed pulmonary infiltrates and rebound splenomegaly, a second patient experienced fever and hypoxic respiratory failure | ||||
| 47 | 22 | Retrospective | 1-y OS of 100% in patients with a good response to ruxolitinib vs 60% in others | Continuing ruxolitinib until conditioning without tapering resulted in no unexpected SAEs |
| 36 | 14 | Retrospective | Engraftment in 13 patients (93%); graft fibrosis (n = 1) and treatment-related sepsis (n = 1) | Tapering ruxolitinib until conditioning did not result in unexpected SAEs |
| 48 | 11 | Retrospective | Good engraftment rates | Differing schedules of ruxolitinib tapering associated with high engraftment rates |
| Reference . | # Patients . | Study Design . | Results . | Conclusions . |
|---|---|---|---|---|
| 38 | 100 | Retrospective | No adverse impact on early outcomes of HCT | Continuing JAK inhibitor therapy near to start of conditioning therapy is associated with very low risk of withdrawal symptoms |
| HCT was delayed in 2 patients due to significant clinical events following JAK 1/2 inhibitor discontinuation: 1 patient developed pulmonary infiltrates and rebound splenomegaly, a second patient experienced fever and hypoxic respiratory failure | ||||
| 47 | 22 | Retrospective | 1-y OS of 100% in patients with a good response to ruxolitinib vs 60% in others | Continuing ruxolitinib until conditioning without tapering resulted in no unexpected SAEs |
| 36 | 14 | Retrospective | Engraftment in 13 patients (93%); graft fibrosis (n = 1) and treatment-related sepsis (n = 1) | Tapering ruxolitinib until conditioning did not result in unexpected SAEs |
| 48 | 11 | Retrospective | Good engraftment rates | Differing schedules of ruxolitinib tapering associated with high engraftment rates |